Real-world efficacy and retention of guselkumab in psoriatic arthritis: insights from a 12-month multicenter study
{{output}}
Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects joints, skin, and other structures. Guselkumab, an IL-23 inhibitor, has shown efficacy in clinical trials, but real-world data on its long-term ... ...
